Literature DB >> 7678301

B epitopes and selection pressures in feline immunodeficiency virus envelope glycoproteins.

G Pancino1, C Chappey, W Saurin, P Sonigo.   

Abstract

In order to map linear B epitopes in feline immunodeficiency virus (FIV) envelope glycoproteins (Env), a random library of FIV Env polypeptides fused to beta-galactosidase and expressed in Escherichia coli was screened by using sera from experimentally FIV-infected cats. We mapped five antibody-binding domains in the surface envelope glycoprotein (SU1 to SU5) and four in the transmembrane envelope glycoprotein (TM1 to TM4). Immunological analysis with 48 serum samples from naturally or experimentally infected cats of diverse origins revealed a broad group reactivity for epitopes SU2, TM2, and TM3, whereas SU3 appeared as strictly type specific. To study selection pressures acting on the identified immunogenic domains, we analyzed structural constraints and distribution of synonymous and nonsynonymous mutations (amino acids unchanged or changed). Two linear B epitopes (SU3 and TM4) appeared to be submitted to positive selection for change, a pattern of evolution predicting their possible involvement in antiviral protection. These experiments provide a pertinent choice of oligopeptides for further analysis of the protective response against FIV envelope glycoproteins, as a model to understand the role of antibody escape in lentiviral persistence and to design feline AIDS vaccines.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 7678301      PMCID: PMC237417     

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  42 in total

1.  Comparison of two host cell range variants of feline immunodeficiency virus.

Authors:  T R Phillips; R L Talbott; C Lamont; S Muir; K Lovelace; J H Elder
Journal:  J Virol       Date:  1990-10       Impact factor: 5.103

2.  Simple methods for estimating the numbers of synonymous and nonsynonymous nucleotide substitutions.

Authors:  M Nei; T Gojobori
Journal:  Mol Biol Evol       Date:  1986-09       Impact factor: 16.240

3.  Amino acid substitutions in structurally related proteins. A pattern recognition approach. Determination of a new and efficient scoring matrix.

Authors:  J L Risler; M O Delorme; H Delacroix; A Henaut
Journal:  J Mol Biol       Date:  1988-12-20       Impact factor: 5.469

4.  B cell epitope mapping of human immunodeficiency virus envelope glycoproteins with long (19- to 36-residue) synthetic peptides.

Authors:  A R Neurath; N Strick; E S Lee
Journal:  J Gen Virol       Date:  1990-01       Impact factor: 3.891

5.  Analysis of sequence diversity in hypervariable regions of the external glycoprotein of human immunodeficiency virus type 1.

Authors:  P Simmonds; P Balfe; C A Ludlam; J O Bishop; A J Brown
Journal:  J Virol       Date:  1990-12       Impact factor: 5.103

6.  Infection of peritoneal macrophages in vitro and in vivo with feline immunodeficiency virus.

Authors:  D Brunner; N C Pedersen
Journal:  J Virol       Date:  1989-12       Impact factor: 5.103

7.  Feline leukemia virus infection as a potentiating cofactor for the primary and secondary stages of experimentally induced feline immunodeficiency virus infection.

Authors:  N C Pedersen; M Torten; B Rideout; E Sparger; T Tonachini; P A Luciw; C Ackley; N Levy; J Yamamoto
Journal:  J Virol       Date:  1990-02       Impact factor: 5.103

8.  Feline immunodeficiency virus: a neurotropic lentivirus.

Authors:  S W Dow; M L Poss; E A Hoover
Journal:  J Acquir Immune Defic Syndr (1988)       Date:  1990

9.  Molecular cloning of a novel isolate of feline immunodeficiency virus biologically and genetically different from the original U.S. isolate.

Authors:  T Miyazawa; M Fukasawa; A Hasegawa; N Maki; K Ikuta; E Takahashi; M Hayami; T Mikami
Journal:  J Virol       Date:  1991-03       Impact factor: 5.103

10.  Human immunodeficiency virus type 1 neutralization epitope with conserved architecture elicits early type-specific antibodies in experimentally infected chimpanzees.

Authors:  J Goudsmit; C Debouck; R H Meloen; L Smit; M Bakker; D M Asher; A V Wolff; C J Gibbs; D C Gajdusek
Journal:  Proc Natl Acad Sci U S A       Date:  1988-06       Impact factor: 11.205

View more
  22 in total

1.  Vaccination with inactivated virus but not viral DNA reduces virus load following challenge with a heterologous and virulent isolate of feline immunodeficiency virus.

Authors:  M J Hosie; T Dunsford; D Klein; B J Willett; C Cannon; R Osborne; J Macdonald; N Spibey; N Mackay; O Jarrett; J C Neil
Journal:  J Virol       Date:  2000-10       Impact factor: 5.103

2.  Enhancement of feline immunodeficiency virus (FIV) infection after DNA vaccination with the FIV envelope.

Authors:  J Richardson; A Moraillon; S Baud; A M Cuisinier; P Sonigo; G Pancino
Journal:  J Virol       Date:  1997-12       Impact factor: 5.103

3.  Sequential CD134-CXCR4 interactions in feline immunodeficiency virus (FIV): soluble CD134 activates FIV Env for CXCR4-dependent entry and reveals a cryptic neutralization epitope.

Authors:  Aymeric de Parseval; Chris K Grant; K Jagannadha Sastry; John H Elder
Journal:  J Virol       Date:  2006-03       Impact factor: 5.103

4.  Variable constraints on the principal immunodominant domain of the transmembrane glycoprotein of human immunodeficiency virus type 1.

Authors:  R Merat; H Raoul; T Leste-Lasserre; P Sonigo; G Pancino
Journal:  J Virol       Date:  1999-07       Impact factor: 5.103

5.  A neutralizing antibody-inducing peptide of the V3 domain of feline immunodeficiency virus envelope glycoprotein does not induce protective immunity.

Authors:  S Lombardi; C Garzelli; M Pistello; C Massi; D Matteucci; F Baldinotti; G Cammarota; L da Prato; P Bandecchi; F Tozzini
Journal:  J Virol       Date:  1994-12       Impact factor: 5.103

6.  Human monoclonal antibodies for the immunological characterization of a highly conserved protein domain of the hepatitis C virus glycoprotein E1.

Authors:  K Siemoneit; M da S Cardoso; K Koerner; A Wölpl; B Kubanek
Journal:  Clin Exp Immunol       Date:  1995-08       Impact factor: 4.330

Review 7.  Feline immunodeficiency virus: an interesting model for AIDS studies and an important cat pathogen.

Authors:  M Bendinelli; M Pistello; S Lombardi; A Poli; C Garzelli; D Matteucci; L Ceccherini-Nelli; G Malvaldi; F Tozzini
Journal:  Clin Microbiol Rev       Date:  1995-01       Impact factor: 26.132

8.  Serum neutralization of feline immunodeficiency virus is markedly dependent on passage history of the virus and host system.

Authors:  F Baldinotti; D Matteucci; P Mazzetti; C Giannelli; P Bandecchi; F Tozzini; M Bendinelli
Journal:  J Virol       Date:  1994-07       Impact factor: 5.103

9.  Antibodies generated in cats by a lipopeptide reproducing the membrane-proximal external region of the feline immunodeficiency virus transmembrane enhance virus infectivity.

Authors:  Simone Giannecchini; Anna Maria D'Ursi; Cinzia Esposito; Mario Scrima; Elisa Zabogli; Giulia Freer; Paolo Rovero; Mauro Bendinelli
Journal:  Clin Vaccine Immunol       Date:  2007-06-27

10.  DNA vaccination affords significant protection against feline immunodeficiency virus infection without inducing detectable antiviral antibodies.

Authors:  M J Hosie; J N Flynn; M A Rigby; C Cannon; T Dunsford; N A Mackay; D Argyle; B J Willett; T Miyazawa; D E Onions; O Jarrett; J C Neil
Journal:  J Virol       Date:  1998-09       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.